|
Index | - | P/E | - | EPS (ttm) | -12.50 | Insider Own | 0.70% | Shs Outstand | 19.40M | Perf Week | -0.95% |
Market Cap | 153.15M | Forward P/E | - | EPS next Y | -2.65 | Insider Trans | 172.84% | Shs Float | 5.54M | Perf Month | -46.11% |
Income | - | PEG | - | EPS next Q | -0.49 | Inst Own | 46.10% | Short Float | 0.72% | Perf Quarter | -47.37% |
Sales | - | P/S | - | EPS this Y | -92.40% | Inst Trans | - | Short Ratio | 0.58 | Perf Half Y | - |
Book/sh | 36.28 | P/B | 0.23 | EPS next Y | -17.30% | ROA | - | Target Price | 24.67 | Perf Year | - |
Cash/sh | 6.42 | P/C | 1.29 | EPS next 5Y | - | ROE | - | 52W Range | 6.88 - 23.58 | Perf YTD | -46.04% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -64.76% | Beta | - |
Dividend % | - | Quick Ratio | 23.50 | Sales past 5Y | - | Gross Margin | - | 52W Low | 20.80% | ATR | 1.66 |
Employees | 22 | Current Ratio | 23.50 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 39.35 | Volatility | 15.39% 18.59% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.75 | Prev Close | 8.16 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 68.54K | Price | 8.31 |
Recom | 1.50 | SMA20 | -11.52% | SMA50 | -34.93% | SMA200 | -37.55% | Volume | 53,219 | Change | 1.84% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California. | ||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite